Lexicon Pharmaceuticals Inc (LXRX) Price

Competition Batters Novo Nordisk Market Dominance

Novo Nordisk's stock has fallen over 58% in the past year as its dominance in the GLP-1 weight-loss market is challenged by intense competition, slowing growth, and looming patent expirations. While the company defends its position with strategic acquisitions and pipeline diversification, analyst sentiment is sharply divided, reflecting a fundamental debate over its valuation and future prospects.